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ABSTRACT
Introduction: Childhood blepharokeratoconjunctivitis is a common lid margin inflammation with
secondary ocular surface disease. Its etiology is unclear and there are no randomized controlled trials
to support the superiority of any treatment option.
Areas covered: We searched the following databases; Cochrane Central Register of Controlled Trials,
Ovid MEDLINE and affiliated Ovid databases, EMBASE, the ISRCTN registry, Clinical- Trials.gov and the
World Health Organization International Clinical Trials Registry Platform. Due to the paucity of pediatric
data we also considered information from articles focused on adults.
Expert commentary: Treatment is based on the assumption that the mechanisms of BKC and rosacea
keratitis are the same: meibomian gland dysfunction, bacterial colonisation of the lid margin, delayed
type hypersensitivity, Demodex folliculorum, genetic predisposition and Toll-like receptors inducing
release of pro-inflammatory cytokines. Generally accepted grading scales are needed. Randomized
clinical trials are needed to evaluate treatment options. The effects of antibiotics, immunomodulators,
osmoprotectants and essential fatty acids need further investigation.
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1. Classification and epidemiology
1.1. Classification
Ocular surface disease secondary to lid margin inflamma-
tion is a common cause of ocular morbidity in children.
This is now called pediatric blepharokeratoconjunctivitis
(BKC), but other names have been used including ocular
rosacea, phlyctenular keratitis, meibomian keratoconjuncti-
vitis, nontuberculous keratitis, or staphylococcal blepharo-
keratitis. There are a range of clinical features including
conjunctivitis, episcleritis, phlyctenulosis, keratitis, corneal
vascularization, and corneal scarring. It is not known
whether these various phenotypes reflect differences in
pathogenesis and disease entity or levels of disease activ-
ity. Corneal disease in children is more likely to be severe
and progress to significant vision loss even with mild lid
margin inflammation than for adults. The proportion of
children who subsequently progress to an adult phenotype
of BKC or rosacea is unknown, but many resolve perma-
nently before adulthood.
Chronic blepharitis is a disorder of the lid margins that can
involve the anterior lid margin (lash follicles) and/or the pos-
terior lid margin (meibomian glands). Both can lead to corneal
disease. In children, posterior blepharitis is more prominent
than anterior changes. Keratitis is uncommon in acute ble-
pharitis related to styes (hordeolum externum), impetigo,
herpes simplex infection, or infected meibomian cysts (acute
chalazion, hordeolum internum).
1.2. Epidemiology
The age of onset of BKC is bimodal with a peak at 4–5 years [1]
and a second peak in adolescence. There may be an interval of
several months between the onset of symptoms and diagnosis
suggesting that it is poorly recognized and probably under-
diagnosed. It is not clear if males or females are more com-
monly affected. Some authors suggest a female predilection
(48–87%) [1]. In other studies, the ratio was about 1:1 (1.6 to 1
[1], 1 to 1 [1], 1 to 1.2 [1]). The male-to-female ratio in rosacea
has been reported to be 30–70% [1]. Although it has been
reported that disease is more severe in South Asian and
Middle-Eastern children [1], a severe phenotype has also
been described in white adolescents [1]. There are no popula-
tion-based studies to confirm or refute a significant associa-
tion with ethnicity.
Several differential diagnoses for BKC should be consid-
ered. The most frequent cause for diagnostic confusion is
chronic allergic eye disease (vernal keratoconjunctivitis, atopic
keratoconjunctivitis) which differs from BKC in that there is
often associated asthma or atopic dermatitis including facial
and lid dermatitis, marked itch, and a significant papillary
response, possibly with giant papillae in the upper tarsal con-
junctiva or limbus. In some cases, atopic eye disease and BKC
can coexist. Other causes for chronic ocular surface inflamma-
tion in children are rare but the presence of a molluscum
contagiosum lesion close to the lid margin should be
excluded. Herpes simplex keratitis should be excluded if
there is unilateral disease. Phlyctenules have a reported
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association with tuberculosis and very rarely with helminthia-
sis, leishmaniasis, and candidiasis. In areas where tuberculosis
is endemic, a child with a phlyctenule should be screened for
tuberculosis (e.g. Quantiferon, chest X-ray). Lash or eyebrow
infestation by crab lice (Phthirus pubis) can cause low-grade
irritation and conjunctivitis and mimic the lash crusts of ante-
rior blepharitis, because of the possibility of sexual abuse of
children with crab lice infestation of the lashes a pediatrician
should be involved.
2. Methods
We searched the following databases, using the search
terms ‘blepharokeratoconjunctivitis,’ OR ‘BKC,’ OR ‘blephar-
okeratitis,’ OR ‘blepharoconjunctivitis,’ OR ‘ocular rosacea;’
Cochrane Central Register of Controlled Trials (CENTRAL)
(which contains the Cochrane Eyes and Vision Group
(CEVG) Trials Register) (latest issue), Ovid MEDLINE, Ovid
MEDLINE In-Process and Other Non-Indexed Citations,
OvidMEDLINE Daily, Ovid OLDMEDLINE (January 1946 to
present), EMBASE (January 1980 to present), the ISRCTN
registry (www.isrctn.com/editAdvancedSearch), Clinical
Trials.gov (www.clinicaltrials.gov), and the World Health
Organization International Clinical Trials Registry Platform
(ICTRP) (www.who.int/ictrp/search/en) [2]. Articles written
in languages other than English or German were not con-
sidered. We excluded articles which we regarded irrelevant
according to the abstract. This provided 33 articles match-
ing our criteria. We also manually collected articles men-
tioned in the reference lists from PubMed. Due to the lack
of randomized controlled trials in this field of research, we
included case reports, retrospective studies, and review arti-
cles. Information concerning the diagnosis and pathophy-
siology of BKC in adults was extracted because of the
paucity of studies specifically addressing these topics in
children. This provided a total number of 99 results on
which this review article is based.
3. Diagnosis
The diagnosis of BKC is based on a characteristic pattern of
symptoms and clinical signs. The symptoms of early BKC
include eye rubbing with chronically uncomfortable red eyes,
photophobia, and epiphora [3–5]. There may be crusting of
the lids in the morning, but discharge is not a major feature.
Frequently, there is a history of recurrent chalazia.
Occasionally, the disease can be relatively asymptomatic
until photophobia, reduced vision, or a corneal opacity alerts
the patient or parents. The disease can be markedly asym-
metric or even unilateral.
3.1. Lid
Blepharitis signs include crusting with scales and collarettes at
the base of the lashes (anterior blepharitis) and telangiectasia
of the lid margin vessels and gaping and inspissation of the
meibomian gland openings (posterior blepharitis) (Figure 1)
with expression of yellow-white meibum following gentle lid
pressure [6]. The lid margins may be diffusely hyperemic and
thickened and there may be one or more chalazia. Chronic
changes include distortion or abnormal placement of meibo-
mian glands, loss of lashes, depigmentation of the skin, mal-
position of eyelashes, keratinization of the lid margin, and
there can be notching of the lid margin [7]. However, in
some individuals, the alteration in appearance of the lid mar-
gin and meibomian glands may be minimal.
3.2. Skin
In adults, the clinical signs of isolated blepharitis and keratitis
are similar to those presenting in association with cutaneous
Figure 1. a lnspissated meibomian gland, telangiectasia, papillary changes of the palpebral conjunctiva b Telangiectasia, lid margin thickening and irregularity,
keratinisation of the lid margin, c Collarettes (keratin scales and crusts encircling eyelash bases) d Corneal staining with fluorescein.
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rosacea, and it is unclear whether there are distinctive disease
mechanisms [8]. Most children with BKC do not have facial
skin changes but there is an association with atopic dermatitis
and acne vulgaris. In children, the association of BKC with
facial rosacea is less common than in adults [9], but its pre-
valence is possibly underestimated [10] and acne vulgaris and
rosacea should be considered if ocular symptoms associated
with facial dermatosis [11]. The ophthalmologist should be
able to distinguish acne vulgaris from papulopustolar rosacea.
Telangiectasia and flushing are associated with rosacea, come-
dones are a hallmark of acne [9].
3.3. Conjunctiva
Conjunctival signs include hyperemia, micropapillae, folliculo-
sis, mild chemosis, and the formation of phlyctenules. In
severe disease, there may be an intense tarsal micropapillary
response and infiltrate with a reactive ptosis and focal or
diffuse limbitis. A conjunctival phlyctenule (or phlycten) is an
acute inflammatory nodule most commonly seen at the lim-
bus topped by a small white collection of polymorphonuclear
leukocytes and an apical epithelial defect. Conjunctival phlyc-
ten usually resolve completely and rapidly following treat-
ment, but there may be a characteristic triangular segment
of vascularization and scarring if there has been corneal invol-
vement. Subconjunctival crystals are not always present but
may be a specific sign for this condition [12].
3.4. Meibomian glands
Meibomian gland dysfunction (MGD) causes poor tear quality
and an evaporative dry eye; the tear film break-up time, the
Schirmer I test, and tear osmolarity are abnormal in adult
patients with BKC [13,14], but as these tests require a degree
of patient cooperation, they are seldom used in children. In
adults, the morphology of the meibomian glands is altered
following chronic inflammation, which can be macroscopically
visualized by meibography using transillumination of the lid
[15] or infrared imaging with computerized image analysis to
estimate meibomian gland atrophy [16]. The relevance of the
reported changes, e.g. gland dropout [17] in children in whom
the course of disease may have been much shorter, is
unknown.
3.5. Cornea
There is a spectrum of corneal changes, which can be multi-
focal. In mild cases, there may only be punctate epithelial
lesions demonstrated with fluorescein, especially over the
inferior third of the cornea, which may be secondary to eva-
porative dry eye or represent direct corneal involvement in
BKC (Figure 2). In more severe disease, there can be corneal
epithelial macrodefects, peripheral keratitis (marginal kerati-
tis), or central keratitis with opaque corneal infiltrates some-
time overlain by an epithelial defect, corneal thinning and
perforation, secondary corneal vascularization, and scarring.
This can lead to irregular astigmatism [18]. Each of these
problems can lead to loss of vision and amblyopia, emphasiz-
ing the importance of early diagnosis and effective treat-
ment [1].
3.6. Grading
There is no agreed classification of disease subtypes or disease
activity. Different grading systems for MGD have been pro-
posed [13]. Viswalingam et al. classified BKC based on the
severity of lid and conjunctival signs as well as corneal invol-
vement [19]. Hamada et al. graded activity and tissue damage
from 0 (no inflammation of damage) to 3 (severe inflammation
or damage) [20]. They considered parameters such as meibo-
mian gland duct dilation, retro-placement of meibomian gland
duct orifices, and migration of the mucocutaneous junction. In
adult dry eye disease, corneal staining with grades from 0 to 5
is considered an indicator of disease activity, and Hamada
et al. incorporated this into their grading system. Corneal
vascularization, formation of pannus (equal to less or more
Figure 2. a Active keratitis with peripheral corneal vascularization b Central corneal vascularisation with central scarring c Punctate corneal epithelial defects,
staining with fluorescein, and early treat film break up d Residual corneal scar without active inflammation.
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than 3 clock hours, centripetal extension), corneal scarring,
and peripheral thinning are used to grade corneal damage.
However, this grading system has not been externally vali-
dated and is not in common clinical use. In practice, any
system which requires detailed assessment can be difficult to
perform in young children who have photophobia.
4. Pathophysiology
The proposed mechanisms that lead to BKC are principally
derived from animal models and studies of rosacea, blephar-
okeratitis, and MGD in adults. It is assumed that the same
mechanisms are active in children. It is not known whether
the different clinical features of BKC are the result of different
disease processes, or the result of a common pathology mod-
ified by local or environmental factors. There is broad con-
sensus on certain key probable pathophysiological drivers in
adult disease [20,21]:
● MGD: hyperkeratinization and terminal duct obstruction
with qualitative and quantitative (usually hyposecretion)
changes in the glandular secretion (meibum), frequently
with inflammation of the meibomian glands and adja-
cent tissues and later atrophy of the glands (dropout). It
is still unclear whether inflammation is the cause or the
consequence of gland obstruction and whether the che-
mical changes of meibum are primary or secondary to
bacterial action [22].
● Bacterial colonization of the lid margin with Staphylococcus
sp., Propionibacterium acnes, and Corynebacteria: bacterial
lipopolysaccharides stimulate the production and release
of proinflammatory cytokines such as TNF-α from the ocu-
lar surface; bacterial phospolipase A2 catalyzes the release
of arachidonic acid from meibum that leads to the forma-
tion of prostaglandins and leukotrienes, while the release
of free fatty acids destabilizes the tear film and promotes
inflammation by neutrophil chemotaxis [23].
● Delayed type hypersensitivity response to bacterial pro-
ducts (e.g. Staphylococcus aureus protein A, ribitol teichoic
acid) causing ocular surface inflammation, although other
antigens may be involved [24].
● A genetic contribution is suggested by reports of a high
prevalence in some ethnic groups and human leukocyte
antigen associations [25]. A recent genome-wide associa-
tion study identified a single-nucleotide polymorphism
associated with rosacea [26].
● Dry eye disease, tear film instability, and hyperosmolarity
with secondary inflammation involve pro-inflammatory
cytokines and activation of several matrix metalloprotei-
nases. Toll-like receptors 2 and 4 have been suggested to
be part of the rosacea pathophysiological pathway. They
respond to physical or chemical stress and can also be
triggered by microbes such as Demodex. Upon activation,
they induce the release of pro-inflammatory cytokines
[27,28].
● TNF-α inhibitors (e.g. Infliximab) have successfully been
used off-label in adults for the treatment of granuloma-
tous rosacea [29]. Cytokines, chemokines, and Toll-like
receptors may become potential targets for future ther-
apeutic interventions in rosacea and possibly BKC.
● A proposed role for Demodex parasites is unproven in BKC
[30]. Studies in rosacea have shown a focally higher den-
sity of Demodex folliculorum mites in the pilosebaceous
units, but it is unclear whether this is cause or effect [31].
5. Treatment
Therapy targets the underlying blepharitis and specific inflam-
matory changes (Table 1) [21]. There are no controlled clinical
trials to guide therapy [8]. Many cases of BKC require pro-
longed treatment and, even with all available options, for
some it is difficult to achieve good inflammatory control.
However, as the prognosis for resolution is good for children,
the treatment aims to control the disease and minimize long-
term damage until the inflammation lessens with time.
5.1. General principles of treatment in children
Treating children using drops or lid hygiene, especially small
children, can be difficult. Lid hygiene may not be possible
without upset in small children and if this is the case, families
should be encouraged to apply what the child will tolerate,
e.g. lid margin cleaning or warm compresses only. Older chil-
dren (7 years and older) should be encouraged to carry out
the lid hygiene by themselves, but may need supervision.
Older children should be encouraged and supported to
administer eye drops themselves. Single unit vials can be used
to allow children to take the drops to school without fear of
‘losing the drop bottle.’ The number and frequency of different
medications should be minimized, within the boundaries of
achieving ensuring satisfactory control, to avoid confusion and
aid compliance. Treatment has to concentrate on those agents
which are most likely to deliver a therapeutic result. If it is crucial
to instill drops into small children to prevent serious ocular tissue
damage or visual loss, parents can be taught techniques of
efficient and safe restraint to allow this.
5.2. Lid hygiene
Lid hygiene is a widely accepted mechanical approach to MGD
and blepharitis. Though nonstandardized and comparative
evidence-based recommendations are not available (level of
evidence II/III), most experts consider lid hygiene a low-cost
and effective treatment [6]. It is advisable in all cases of acute
or chronic lid inflammation [32]. Acute or inflamed chalazia
should be treated daily with warm moist lid compresses
(Figure 3). A short course of topical antibiotics can be used.
Meibomian cysts tend to resolve spontaneously and in most
cases in children can be safely left to do so, but they can be
incised or injected locally with long-acting steroids if they do
not resolve, or if they affect vision by altering lid position,
although this often requires a general anesthetic in children
[33]. For chronic disease, lid hygiene is usually recommended,
for which there are three components: warm compresses, lid
massage, and cleaning of lid debris. A warm compress helps to
soften any crusts and inspissated meibum on the lid margin.
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Massage of the lid margin, using a finger or cotton bud, is
thought to improve the outflow of meibum. This can then be
followed by physical cleaning of the posterior lid margin and
the base of the eye lashes with a moistened cotton bud or, in
smaller children, a moistened flannel held taut over the index
finger. Although advice is often provided to use water which
Table 1. Therapeutic options for management of pediatric blepharokeratoconjunctivis.
Option Agent Protocol
Lid hygiene Lid margin cleaning (most important): any of these methods: cotton bud/swab soaked in
water, with or without baby shampoo/bicarbonate; flannel wrapped tightly around
index finger and soaked in water, with or without baby shampoo/bicarbonate;
commercial lid wipes [4,6]
Topical lubricants Hyaluronic acid 0.1%
Carmellose 0.5%
etc.
PRN [21,42,66]
Topical antihistamines/mast
cell inhibitor
G Olopatadine 0.1%
G cromoglycate 2%
G nedocromil sodium 2%
G lodoxamide 0.1%
BD
QDS
BD-QDS
BD-QDS
Topical antibiotic [6,21] Oc chloramphenicol 1%
Oc fusidic acid 1%
Oc erythromycin 0.5%
G. moxifloxacin 0.5%
G. levofloxacin 0.5%
G. ofloxacin 0.3%
G azithromycin 1.5%
Oc metronidazole 0.75%
OD - BD
BD
OD - BD
BD for 3 days then OD-BD for 3 days every two to four weeks
Facial skin
Oral antibiotic Erythromicin (<12 years)
Doxycycline (>12 years)
250mg (or age appropriate dosage) BD for at least 6 to 12 weeks [8]
50-100mg OD (or weight appropriate dosage) for at least 6-12 weeks [6,21,42]
Topical ocular anti-
inflammatory [6,21,42]
G fluorometholone 1%
G rimexolone 1%
G loteprednol 0.5%
G dexamethasone 0.1%
G ciclosporin A 0.05-2%
OD-1 hourly dependent on severity
OD-QDS
Omega-3 oil Flaxseed oil
Cod liver oil
2.5ml for 6 months or longer [62,63]
Age appropriate dose
Immunosuppression mycophenolate mofetil
azathioprine
prednisolone
Age appropriate dose [18]
Supervision by pediatrician
Interventional management Rigid contact lens
Fine needle diathermy
Corneal glue/tectonic keratoplasty
Lamellar or penetrating keratoplasty
For irregular astigmatism
For progressive vascularization
For perforation
For scar
Figure 3. Lid margin cleaning is the most important procedure. (a) After having applied warm compresses to the eye lids the lid margin can be cleaned either
awith a cotton bud/swab soaked in water, with or without baby shampoo/bicarbonate, (b) with a flannel wrapped tightly around index finger and soaked in water, with or
without baby shampoo/bicarbonate or with commercial lid wipes. (c, d) A nurse should instruct parents and children in how to safely apply drops/ointment to the eye.
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has been boiled, there is no evidence that the use of unster-
ilized tap water is harmful nor is there evidence that saline is
better than water. There is limited evidence whether either
home-made (e.g. diluted baby shampoo, bicarbonate of soda
solution) or proprietary (e.g. hypochloric acid 0.01%) products
containing mild detergents or astringents enhance the effec-
tiveness of plain water or saline [6]. Similarly, the role of steam
goggles in children is unclear. Lid hygiene, usually undertaken
once to twice daily, takes several weeks to have an effect and
long-term treatment is often required to prevent relapse and
can be extremely difficult or impossible to perform in small
children; older children should be supported to perform this
themselves. It is very important for clinical staff to spend the
time carefully explaining the lid hygiene technique to the
child (if age appropriate) and the family, to ensure it is per-
formed using the right method.
5.3. Antibiotics
Both topical and systemic antibiotics have been used in the
treatment of BKC [32,33].
5.3.1. Topical antibiotics and antiseptics
Short-term use of topical antibiotics may be required when
there is blepharitis-related acute infection of the lids, such as
styes and infected meibomian cysts, but active infection is not
a major component of BKC. The main rationale for using
topical antibiotics (either on the lid margin after hygiene or
instilled in the eye) for BKC is to reduce bacterial colonization
of the lid margin. Chloramphenicol drops or ointment, ery-
thromycin ointment, or azithromycin drops have all been used
(level of evidence 4) [34]. Whilst chloramphenicol and erythro-
mycin can be applied twice daily for prolonged periods, the
optimal application schedule for topical azithromycin in BKC is
unknown. Topical azithromycin has a long tissue half-life.
Animal models have shown that after multiple applications
of azithromycin 1.5%, tissue levels remained above the mini-
mal inhibitory concentration for common ocular bacteria for
up to a week [35]. Treatment at intervals has therefore been
used in childhood BKC and adult blepharitis. Only one study
on childhood BKC is available, which used a 6-month course:
in the first and second month, azithromycin was administered
twice daily for 3 days starting on day 1, 11, 21 (and no
treatment between these cycles); in the third and fourth
month, twice daily for 3 days starting on day 1 and 15; and
finally in month 5 and 6, twice daily for 3 days starting on day
1 [36]. Stinging and ocular surface irritation are the most
frequent adverse events [37] and can require discontinuation
of the treatment [36]. In a multicenter open-label study, Haque
et al. report that in adults azithromycin 1% causes a significant
decrease in coagulase-negative staphylococci and corynebac-
terium bacterial colonization and a significant improvement in
clinical signs and symptoms (level of evidence 4) [38]. In a
prospective, observational, open-label clinical trial of topical
azithromycin, Foulks et al. showed that in adults, the spectro-
scopic behavior of the meibomian gland lipids as well as
clinical signs of MGD improves after therapy (level of evidence
4) [39]. A combined treatment of children with dexametha-
sone and azithromycin was reported to be safe [40].
Lid cleaning with chlorhexidine 0.02%, an antiseptic, may
help if there is severe lid margin inflammation (level of evi-
dence 4) [20]. Topical metronidazole (0.75% or 1%) gel can
help facial skin disease [41]. It is not clear how long topical
antibiotic use should continue and whether a short course is
sufficient or whether longer term chronic treatment is
required in both adults and children.
5.3.2. Systemic antibiotics
An effect of oral antibiotics in controlling symptoms in adults
with ocular rosacea and MGD has been shown in several
clinical studies (level of evidence 5) [23]. Oral antibiotics are
usually used long term (at least 6–12 weeks) in low-dose (sub-
antimicrobial) levels. Patients with active BKC or visually sig-
nificant keratitis should be treated with long-term low-dose
oral antibiotic and a course of an oral antibiotic should also be
considered if there is marked blepharitis that is difficult to
control with simple measures or there have been recurrent
meibomian cysts. Erythromycin is the macrolide most com-
monly prescribed to children at doses ranging from 12.5 to
40 mg/kg body weight per day (level of evidence 4) [42]. The
reported duration of systemic antibiotic treatment ranges
from 1 to 23 months [18]. Clarithromycin has also been suc-
cessfully used to treat BKC [23]. Newer macrolide antibiotics
such as azithromycin may be as effective as erythromycin and
have a longer half-life with greater tissue accumulation, allow-
ing for less frequent administration [43]. From the age of
12 years, tetracyclines can be used. There are no published
evidence-based recommendations for the dose or duration of
tetracyclines in the treatment of children with MGD or BKC.
Oxytetracycline can be used (500 mg t.i.d for a period of
4 months and 250 mg t.i.d. for a period of 8 weeks or longer);
alternatively, many patients find it more convenient to use
100 mg doxycycline o.d. for 4 weeks followed by 50 mg o.d.
for 8 weeks (can be used longer). Lower doses may be as
effective. Though anti-inflammatory effects may be observed
after 6 weeks of antibiotic treatment, the latency might be
longer. Therefore, we recommend a minimum treatment of
12 weeks.
The mechanism of action for long-term low-dose oral
macrolides and tetracyclines is unknown, but may include
both an antimicrobial and an anti-inflammatory effect, inhibit-
ing lid margin bacterial lipase activity that alters meibum
composition and releases pro-inflammatory mediators from
meibum [6,44].
The most common side effects of tetracyclines are diarrhea,
nausea, headache, photosensitization, vaginal or oral candidia-
sis, and hypersensitivity [6]. Tetracyclines should not be pre-
scribed for children less than 12 years of age due to the risk of
staining of the dental enamel. Macrolides are usually well
tolerated but can also cause gastrointestinal disturbances
[42]. Other oral antibiotics (e.g. amoxicillin–clavulanate, cepha-
losporins) are sometimes used, including when there is intol-
erance or allergy to the more commonly used antibiotics, but
the effectiveness and mechanisms of action of these have not
been established [34].
304 M. C. DANIEL ET AL.
5.4. Topical corticosteroids
Topical corticosteroids are the most effective initial treatment
to control ocular surface inflammation for the majority of
patients with BKC (level of evidence 4) [3,4,6]. A short course
of intensive treatment (e.g. prednisolone 1% or dexametha-
sone 0.1% two hourly) may be required to control severe
inflammation. Where long-term treatment (i.e. for more than
2 months) is required, it is sensible to use a product with a low
risk of causing ocular hypertension and cataract, e.g. fluoro-
metholone 0.1%, loteprednol, or rimexolone, and to rapidly
taper steroids to the lowest dose compatible with symptom
relief. The intraocular pressure should be monitored even with
very low-dose therapy, but this can be challenging in very
small children. Other possible side effects include cataract and
the vulnerability to ocular surface infections, especially herpes
simplex keratitis.
The risk of steroid-induced ocular hypertension following
topical application of corticosteroid has been reported to be
as high as 50–60% [45]. Loteprednol etabonate has been
demonstrated to be safe in pediatric subjects [46] and as
effective in the reduction of signs and symptoms as predniso-
lone acetate with less risk of increasing the intraocular pres-
sure [2,47]. Treatment with a combination of loteprednol
etabonate 0.5%/tobramycin 0.3% may be as effective as the
treatment with dexamethasone 0.1%/tobramycin 0.3% (level
of evidence 1b) [48], but aminoglycosides can cause toxicity
following prolonged use. A sub-tenon’s injection of triamcino-
lone acetonide has been used in noncompliant children (level
of evidence 4) but this can cause problems if there is a con-
sequent steroid-related intraocular pressure rise [49].
5.5. Calcineurin inhibitors
Topical ciclosporin or tacrolimus are alternatives to topical corti-
costeroid to control ocular surface inflammation and have a
steroid-sparing effect. However, the use of these products for
the treatment of BKC is off license. In the USA, ciclosporin A (CSA)
0.05 % (Restasis®, Allergan) and in Europe, CSA 0.1% (Ikervis®,
Santen) are approved for the treatment of dry eye disease. In the
United Kingdom, some specialist centers also use the veterinary
CSA ointment (Optimmune 0.2%) in a special arrangement for
named patients; prior to this, it was common to use local phar-
macy produced 2% CSA dissolved in maize oil.
Calcineurin inhibitors are immunosuppressive agents that
inhibit cell-mediated immunity and are used to treat a wide
range of inflammatory and immune-mediated diseases [50].
CSA forms a complex with intracellular cyclophilin A, resulting
in the inhibition of calcineurin. This prevents T cells from produ-
cing pro-inflammatory agents such as TNF-α, INF-γ, interleukin-4,
and interleukin-2 which mediates activation and proliferation of
T cells. CSA has a slower onset of effect than topical corticoster-
oid and so patients may require supplementary corticosteroid
initially for severe inflammation or rapid symptom relief.
5.6. CSA
In ophthalmology, topical CSA is used for the treatment of
chronic inflammatory conditions in adults (e.g. blepharitis,
MGD, rosacea keratoconjunctivitis, atopic keratoconjunctivitis,
Thygeson’s superﬁcial punctate keratitis, adenoviral opacities,
chronic corneal allograft reaction) [34]. CSA 0.05% has been
shown to be effective in adult patients with MGD in a number
of randomized, controlled trials (level of evidence 1b). CSA
0.05% has been shown to be significantly more effective
than tobramycin/dexamethasone [51].
5.7. Tacrolimus
Tacrolimus (Protopic 0.03%, Astellas Pharma) is a macrolide
lactone. Its potency is reported to be a factor of 10 greater
than CSA [52]. Topical tacrolimus is approved for the treat-
ment of moderate-to-severe atopic dermatitis in adults recal-
citrant to glucocorticoids. Pimecrolimus (Elidel® 1%, MEDA
PHARMA) is approved for the treatment of mild-to-moderate
atopic dermatitis in children aged 2 years and above. It acts
more selectively than tacrolimus and has lower skin penetra-
tion. In a retrospective case series of adult patients with atopic
blepharoconjunctivitis looking at application of therapy to the
lid skin, tacrolimus was more effective and better tolerated
than pimecrolimus without any induced ocular hypertension,
cataract formation, lid skin atrophy, or malignant transforma-
tion (n = 338, mean follow-up 5.7 years) [53]. Tacrolimus
ointment (0.03%) instilled in the eye has been reported to
be effective for the treatment of atopic blepharoconjunctivitis
(n = 20, mean age 10.8 years); however, the pathophysiology
of this differs from nonatopic BKC [48]. Reported adverse
events of treatment with topical calcineurin antagonists are
rare. Lid maceration was reported in one patient treated with
topical CSA 2% [49,54]. Tacrolimus as well as pimecrolimus are
known to cause transient local burning and can possibly
induce herpetic keratitis [52].
The use of systemic immunosuppression at doses for sup-
pression of allograft rejection is associated with a risk of
lymphoma, skin tumors, and granulomatous lymphadenitis
[55]. However, the risk of topical application is debated [56].
In 2005, the Pediatric Advisory Committee of the US FDA
warned about treatment with topical calcineurin inhibitors,
considering the lack of long-term safety data and the potential
risk of malignancies. There are two studies in adults, published
in 2015. A systematic literature search and a separate meta-
analysis on case control and cohort studies reported that
topical treatment with calcineurin inhibitors of atopic derma-
titis was unlikely to be a significant risk factor for lymphoma
[51]. In contrast, a longitudinal post-marketing study identified
5 out of 7457 children treated with pimecrolimus due to
atopic dermatitis who developed a malignancy such as leuke-
mia (2), osteosarcoma (1), and lymphoma (2); local skin malig-
nancies were not detected. The authors considered the
treatment unlikely to be associated with an increased risk of
malignancy [57]. Conjunctival squamous cell carcinomas were
reported after systemic treatment with CSA which has created
concerns that its topical application might have a similar effect
on the ocular surface. In a retrospective interventional case
series, 76 eyes treated with CSA 1% or 2% for a mean period of
2.2 years did not show any microscopic or cytological signs of
malignant transformation after a mean follow-up of 5.9 years
[58]. CSA was undetectable in peripheral blood after topical
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treatment with concentrations of 0.05% or 0.1% for 12 months
[59]. Similarly, the treatment of 156 children with vernal kera-
tokonjunctivitis with concentrations of 1% and 2%, respec-
tively, was reported to safe (mean duration of treatment
3.8 ± 1.09 years) [54,60]. Considering these results and their
potential steroid-sparing effect, calcineurin inhibitors seem to
be safe and effective in the treatment of BKC but there is still
some concern about the lack of extensive randomized clinical
trials or very long-term effects after use in children with BKC.
5.8. Systemic immunosuppression
Systemic immunosuppression for BKC should be considered if
there is inexorable corneal vascularization with opacification,
or corneal melt with threatened or actual perforation [18], and
also to control inflammation and reduce the risk following
keratoplasty or other significant ocular surface surgery.
Options include prednisolone, azathioprine, mycophenolate
mofetil, or CSA (level of evidence 4) [20]. Pediatricians should
be involved and patients may need to be screened for tuber-
culosis (Quantiferon) and immunity to herpes zoster.
5.9. Ancillary treatment: artificial tears and dietary
modification
Dry eye with punctate corneal epithelial erosions occurs sec-
ondary to lid and conjunctival inflammation. Topical lubricants
may support the integrity of the tear film, keep tear osmolarity
close to physiological levels, and dilute inflammatory agents.
They may be a helpful ancillary treatment option for symptom
control (level of evidence 5 in adults), particularly in older
children; care must be taken not to overburden the family
with numerous eye drops [4]. Preservative-free preparations
may be less liable to cause secondary symptoms of ocular
surface toxicity if frequent application is required [61].
The use of oral omega-3 (e.g. flaxseed oil, fish oil) has been
recommended as an ancillary treatment for the control of
ocular surface disease [21]. Experiments in a murine dry eye
disease model suggest that polyunsaturated fatty acids of
omega-3 and omega-6 might act as naturally occurring anti-
inflammatory agents and reduce inflammatory cytokine
expression [62]. In clinical trials in adults with MGD, the oral
intake of omega-3 was shown to suppress the systemic pro-
duction of pro-inflammatory cytokines and eicosanoids (TNF-
α, IL-1b, thromboxane B2, prostaglandin E2) [63]. They may
also affect the polar lipid profiles of meibomian gland secre-
tions [64]. However, it is unclear whether these observations
relate to the disease mechanisms of BKC and whether any
benefit might be expected to accrue in BKC from diet
supplementation.
There are few reports on their use in BKC (level of evidence
4) [21]. In moderate and severe BKC, the anti-inflammatory
effect of omega-3 supplements alone may not be sufficient to
control inflammation [65] but patients often report improve-
ment and some ability to reduce other treatment modalities.
To date, there are no data comparing the efficacy and safety of
oral omega-3 supplements with other anti-inflammatory drugs
such as steroids or calcineurin antagonists. The potential side
effects of the long-term use of flaxseed oil in children are
unknown and, although a maximum treatment of 6 months
has been suggested, there is no evidence to support this
[20,66–68].
6. Severe complications of BKC
Secondary microbial keratitis is rare and should be treated
with intensive broad-spectrum topical antibiotics. An axial
corneal opacity or irregular astigmatism may cause amblyopia
in younger children. Glasses and, if necessary, occlusion for
amblyopia should be prescribed and visual correction may be
improved in older children with a rigid contact lens. Lamellar
or penetrating keratoplasty may be required for severe corneal
scarring that is significantly reducing the vision but is much
higher risk in both children and in those with active ocular
surface inflammation. Attempts can be made to reduce cor-
neal neovascularization using fine needle diathermy or sub-
conjunctival anti-vascular endothelial growth factor agents
[69]. Corneal perforation (Figure 4) should be managed in
the short term with bandage contact lenses if minor and
potentially self-healing, or cyanoacrylate glue but tectonic
keratoplasty may be required (level of evidence 4) [18].
7. Conclusion
BKC is an important cause of ocular morbidity in childhood. It
is under-recognized and there is often a substantial delay in
diagnosis and the initiation of treatment. There is no current
evidence-based consensus on the management of BKC.
Interventions target the specific manifestations affecting lids,
conjunctiva, and cornea. Drug treatment options include topi-
cal steroids and immunosuppressants and topical and sys-
temic antibiotics to control inflammation. Lid hygiene,
dietary modification, and tear supplements have an uncertain
role but are low risk. MGD, bacterial colonization of the mei-
bomian glands, hyperosmolarity of the tear film, and upregu-
lation of inflammatory cytokines may be involved in the
development of BKC. Further research is required to determine
the pathogenesis, and thus guide the management, of BKC
and potentially help define pathways of therapy for different
subgroups of disease.
Figure 4. Corneal perforation with protruding iris in a child with acute keratitis.
A similar but less severe defect was located in the same position of the left eye
(not in picture).
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8. Expert commentary
BKC is a common eye disorder in children, although the pre-
valence is unknown. There is little high-quality evidence to
support the superiority of any specific therapy for BKC and this
is particularly so for pediatric BKC. Treatment and theories of
pathogenesis are based on the assumption that the mechan-
isms of BKC and rosacea keratitis are the same which may or
may not be justified. The diagnostic criteria are poorly defined
and the importance of clinical subgroups is unknown. There
are no generally accepted grading scales, hampering the
quantitative assessment of different treatments in clinical
trials. Accordingly, treatment guidelines are based on limited
evidence.
We tailor treatment to address the specific lid, conjunctival
and corneal signs, and the severity of inflammation (Table 1). It
is important to modify the approach to disease from that in
adults to ensure compliance and to retain engagement of the
patient and their family.
The treatment of acute stages of disease activity with ster-
oids is unspecific and exposes the patient at risk of various
detrimental ocular side effects. CSA is not licensed for this
indication but is effective in clinical practice, although there
are some potential concerns on very long-term use and the
possibility of later local malignancy. Randomized clinical trials
are needed to evaluate the role of the different steroid-sparing
immunomodulators. Also, the role and effects of osmoprotec-
tants and essential fatty acids need further investigation, since
they might serve as valuable additive treatment options with
minimal risk for adverse effects.
9. Five-year view
We believe that within the next 5 years, the goals should be
● to agree a classification of the clinical signs of BKC
according to severity of disease,
● to use this classification to develop and evaluate treat-
ment pathways, and
● to develop a framework for randomized clinical trials of
key treatments to guide therapy.
Key issues
● In developed countries BKC is probably second only to
allergic eye disease as a reason for referral to external eye
disease services. However, the prevalence is unknown.
● The mean of age of onset is between 4 to 5 years. Girls,
South Asian and Middle-Eastern children are affected more
frequently. There is characteristically a significant delay
between the onset of symptoms and diagnosis.
● In a minority of patients there can be sight threatening
complications such as corneal thinning, stromal scarring
and perforation; this is more likely and more serious in
childhood than in adults with blepharitis. In younger
patients corneal opacity can result in visual deprivation
amblyopia.
● A grading of the relative severity of clinical signs such as
diffuse conjunctival inflammation, phlyctenules, corneal
inflammation, scarring and vascularization has not been
agreed. Such a grading would help develop treatment
pathways and support robust clinical trials.
● Hypotheses for the pathogenesis of BKC and pathways for
treatment are largely based on research on blepharitis and
experience treating adult rosacea and rosacea keratocon-
junctivitis. The assumption that there is a shared pathogen-
esis between these conditions may not be valid.
● Treatment with topical corticosteroids and antibiotics is
effective in most cases. Monitoring for unwanted side
effects of treatment is essential and can be more challen-
ging in children. Treatment may be required for several
months.
● Topical and systemic antibiotics may be used singly or in
combination. Chloramphenicol, erythromycin and azithromy-
cin are suitable for topical application. Macrolides and tetra-
cyclines are used for systemic treatment. Tetracyclines should
only be used in children after the age of 12 years. Erythromycin
is a good alternative for younger children. Recent reports
suggest that azithromycin may be more effective.
● Randomized clinical trials are needed to evaluate the rela-
tive benefit of calcineurin inhibitors compared to topical
corticosteroid. Essential fatty acids might serve as valuable
anti-inflammatory treatment options.
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